MAKScientific is a recognized leader in endocannabinoid research and drug development.  The Company is developing a pipeline of orally available small molecule drugs that target important intervention points in the endocannabinoid system.  These targets include the known cannabinoid receptors (CB1 and CB2) as well as key enzymes involved in modulating the system including fatty acid amide hydrolase (FAAH), monoacylglyceral lipase (MGL), N-acylethanolamine-hydrolyzing amidase (NAAA), diacylglycerol lipase (DGL) as well as the cannabinoid transporter system.

The Company has several ongoing collaborations with industry, government and academia which have supported expansion of its drug portfolio to include a library of rationally designed and druggable cannabinergic compounds.  Selected compounds are being advanced for the treatment of chronic liver disease and metabolic diseases, multiple sclerosis, neurodegenerative disorders, inflammatory pain, chemotherapy induced neuropathy and drug addiction.